Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain

Stroke

Volumn 30, Issue 3, 1999, Pages 624-629

  Zhang, Rui Lan ^a   Zhang, Zheng Gang ^a   Chopp, Michael ^a,b  

^a HENRY FORD HOSPITAL   (United States)

^b OAKLAND UNIVERSITY   (United States)

Author keywords

Antibodies; Cell adhesion molecules; Embolism; Plasminogen activator, tissue type; Rats; Selectins; Thrombolysis

Indexed keywords

ALTEPLASE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; PADGEM PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; FIBRINOLYTIC THERAPY; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 0001373003     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.30.3.624     Document Type: Article

References (51)

1. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne M-H, Hennerici M. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study. JAMA. 1995;274:1017-1025.
3. Larrue V, von Kummer R, del Zoppo G, Bluhmki E. Hemorrhagic transformation in acute ischemic stroke: potential contributing factors in the European Cooperative Acute Stroke Study. Stroke. 1997;28:957-960.
4. Lyden PD, Zivin JA. Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence. Cerebrovasc Brain Metab Rev. 1993;5:1-16.
5. Zivin JA. Factors determining the therapeutic window for stroke. Neurology. 1998;50:599-603.
6. Wardlaw JM, Warlow CP, Counsell C. Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke. Lancet. 1997;350: 607-614.
7. Lyden PD, Grotta JC, Levine SR, Marler JR, Frankel MR, Brott TG. Intravenous thrombolysis for acute stroke. Neurology. 1997;49:14-20.
8. Kochanek PM, Hallenbeck, JM. Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke. 1992;23:1367-1379.
9. del Zoppo GJ. Thrombolytic therapy in the treatment of stroke. Drugs. 1997;54(suppl 3):90-98.
10. Chopp M, Zhang ZG. Role of Cell Adhesion Molecules in Neuronal Damage Following Ischemia. WHO Expert Series on Neuroscience 1998. In press.
11. Patarroyo M, Prieto J, Rincon J, Timonen T, Lundberg C, Lindbom L, Asjo B, Gahmberg CG. Leukocyte-cell adhesion: a molecular process fundamental in leukocyte physiology. Immunol Rev. 1990;114:67-108.
12. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell. 1991;67:1033-1036.
13. Bevilacqua MP. Endothelial-leukocyte adhesion molecules. Ann Rev Immunol. 1993;11:767-804.
14. Springer TA. Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu Rev Physiol. 1995;57:827-872.
15. Zhang RL, Chopp M, Zhang ZG, Jiang N, Powers C. The expression of P- and E-selectins in three models of middle cerebral artery occlusion. Brain Res. 1998;785:207-214.
16. Zhang RL, Chopp M, Zaloga C, Zhang ZG, Jiang N, Gautam SC, Tang WX, Tsang W, Anderson DC, Manning AM. The temporal profiles of ICAM-1 protein and mRNA expression after transient MCA occlusion in the rat. Brain Res. 1995;682:182-188.
17. Matsuo Y, Onodera H, Siga Y, Nakamura M, Ninomiya M, Kihara T, Kogure K Correlation between myeloperoxidase-quantified neutrophil accumulation and ischemic brain injury in the rat: effects of neutrophil depletion. Stroke. 1994;25:1469-1475.
18. Mori E, del Zoppo, GJ, Chambers D, Copeland BR, Arfors KE. Inhibition of polymorphonuclear leukocyte adherence suppresses no-reflow after focal cerebral ischemia in baboons. Stroke. 1992;23:712-718.
19. Chen H, Chopp M, Zhang RL, Bodzin G, Chen Q, Rusche JR, Todd III RJ. Anti-CD11b monoclonal antibody reduces ischemic cell damage after transient focal cerebral ischemia in rat. Ann Neurol. 1994;35:447-452.
20. Zhang RL, Chopp M, Jiang N, Tang WX, Prostak J. Manning AM. Anti-ICAM-1 antibody reduces ischemic cell damage after transient but not permanent MCA occlusion in the Wistar rat. Stroke. 1995;26: 1438-1443.
21. Zhang RL, Chopp M, Li Y, Zaloga C, Jiang N, Jones M, Miyasaka M, Ward P. Anti-ICAM-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat. Neurology. 1994;44: 1747-1751.
22. Clark WM, Madden KP, Rothlein R, Zivin JA. Reduction of central nervous system ischemic injury in rabbits using leukocyte adhesion antibody treatment. Stroke. 1991;22:877-883.
23. Frijns CJM, Kappelle LJ, van Gijn J, Nieuwenhuis HK, Sixma JJ, Fijnheer R. Soluble adhesion molecules reflect endothelial cell activation in ischemic stroke and in carotid atherosclerosis. Stroke. 1997;28: 2214-2218.
24. Sobel RRA, Mitchell ME, Fondren G. Intercellular adhesion molecule-1 (ICAM-1) in cellular immune reactions in the human central nervous system. Am J Pathol. 1990;136:1309-1316.
25. Tsirka SE, Gualandris A, Amaral DG, Strickland S. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature. 1995;377:340-344.
26. Tsirka SE, Rogove AD, Strickland S. Neuronal cell death and tPA. Nature. 1996;384:123-124.
27. Carmeliet P, Collen D. Molecular analysis of blood vessel formation and disease. Am J Physiol. 1997;273:H12091-H2104.
28. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med. 1998; 4:228-231.
29. Schaiff WT, Eisenberg PR. Direct induction of complement activation by pharmacologic activation of plasminogen. Coron Artery Dis. 1997; 8:9-18.
30. Bennett WR, Yawn DH, Migliore PJ, Young JB, Pratt CM, Raizner AE. Activation of complement system by recombinant tissue plasminogen activator. J Am Coll Cardiol. 1987;10:627-632.
31. Agostoni A, Gardinali M, Frangi D, Cafaro C, Conciate L, Sponzilli C, Salvioni A, Cugno M, Cicardi M. Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction: a comparison between streptokinase and recombinant tissue-type plasminogen activator. Circulation. 1994;90:2666-2670.
32. Hattori R, Hamilton KK, McEver RP, Sims PJ. Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J Biol Chem. 1989;264:9053-9060.
33. Benzaquen LR, Nicholson-Weller A, Halperin JA. Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med. 1994;179:985-992.
34. Foreman KE, Vaporiciyan AA, Bonish BK, Jones ML, Johnson KJ, Glovsky MM, Eddy SM, Ward PA. C5a-induced expression of P-selectin in endothelial cells. J Clin Invest. 1994;94:1147-1155.
35. Bowes MP, Rothlein R, Fagan SC, Zivin JA. Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy. Neurology. 1995;45:815-819.
36. Zhang RL, Chopp M, Zhang ZG, Jiang Q. A rat model of focal embolic cerebral ischemia. Brain Res. 1997;766:83-92.
37. Tamatani T, Miyasaka M. Identification of monoclonal antibody reactive with the rat homologue of ICAM-1, and evidence for differential involvement of ICAM-1 in the adherence of resting versus activated lymphocytes to high endothelial cells. Int Immunol. 1993;2:166-172.
38. Tamiya Y, Yamamoto N, Uede T. Protective effect of monoclonal antibodies against LFA-1 and ICAM-1 on myocardial reperfusion injury following global ischemia in rat hearts. Immunopharmacology. 1995;29: 53-63.
39. Matsuo Y, Onodera H, Shiga Y, Shozuhara H, Ninomiya M, Kihara T, Tamatani T, Miyasaka M, Kogure K. Role of cell adhesion molecules in brain injury after transient middle cerebral artery occlusion in the rat. Brain Res. 1994;656:344-352.
40. Zhang RL, Chopp M, Zhang ZG. Early (1H) administration of tissue plasminogen activator reduces infarct volume without increasing hemorrhagic transformation after focal cerebral embolization in rats. J Neurol Sci. 1998;160:1-8.
41. Overgaard K, Sereghy T, Boysen G, Pedersen H, Diemer NH. Reduction of infarct volume and mortality by thrombolysis in a rat embolic stroke model. Stroke. 1992;23:1167-1174.
42. Zea Longa Z, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20: 84-91.
43. Zhang ZG, Chopp M. Measurement of myeloperoxidase immunoreactive cells in ischemic brain after transient middle cerebral artery occlusion in the rat. Neurosci Res Commun. 1997;20:85-91.
44. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. 2nd ed. Orlando. Fla: Academic Press; 1986.
45. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR. A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab. 1990;10:290-293.
46. Coughlan AF, Hau H, Dunlop LC, Berndt MC, Hancock WW. P-selectin and platelet activating factor mediate initial endotoxin induced neutropenia. J Exp Med. 1994;179:329-334.
47. Zhang RL, Chopp M, Zhang ZG, Phillips ML, Rosenbloom CL, Cruz R, Manning A. E-selectin in focal cerebral ischemia and reperfusion in the rat. J Cereb Blood Flow Metab. 1996;16:1126-1136.
48. Montrucchio G, Lupia E, De Martino A, Silverstro L, Savu SR, Cacace G, De Filippi PG, Emanuelli G, Camussi G. Plasmin promotes an endothelium-dependent adhesion of neutrophils: involvement of platelet activating factor and P-selectin. Circulation. 1996;93:2152-2160.
49. Harker LA, Hanson SR, Runge MS. Thrombin hypothesis of thrombus generation and vascular lesion formation. Am J Cardiol. 1995;75: 12B-17B.
50. Zhang RL, Zhang ZG, Chopp M. Increased therapeutic efficacy with rt-PA and anti-CD18 antibody treatment of embolic stroke in the rat. Neurology. In press.
51. The Enlimomab Acute Stroke Trial Investigators. The Enlimomab Acute Stroke Trial: final results. Cerebrovasc Dis. 1997;7(suppl 4):18. Abstract.